BillionToOne's Oguzhan Atay explores how advances in liquid biopsy technology offer single-molecule sensitivity to detect and quantify cancer DNA with unprecedented accuracy, improving therapy selection, treatment monitoring, and potentially enabling early-stage cancer diagnosis in the near future.
